Jiangsu Vcare's Novel Drug Vicagrel Receives FDA Approval for Clinical Trials
Published Time:
2021-03-22 17:35
Source:
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced encouraging news regarding its novel antiplatelet drug Vicagrel: The US FDA has provided feedback on the company's submitted IND application for Vicagrel, permitting the company to initiate clinical trials.
Vicagrel has already completed Phase II clinical studies in China. Existing clinical trial results have demonstrated multiple advantages, including rapid onset of action, low dosage, no significant respiratory depression, low bleeding risk, and the design to overcome "clopidogrel resistance." Beyond its application in ACS, it has the potential to further expand its indications to include stroke patients, who are more sensitive to bleeding risks. Following FDA approval, we will initiate multiple international multi-center clinical studies.
Dr. Gong Yanchun, Co-founder and CEO of Jiangsu Vcare, stated: "The IND approval for Vicagrel in the US marks a significant milestone in its clinical development program and the first step towards international expansion. We extend our gratitude to the Vcare team for their decade-long dedication and hard work. The previous Pre-IND meeting proceeded smoothly, with the FDA providing highly positive feedback and commendation for Vicagrel. Moving forward, we will collaborate closely with clinical trial sites and regulatory agencies to accelerate Vicagrel's development, striving to bring this more effective treatment option to cardiovascular disease patients as soon as possible."
About Vicagrel
Vicagrel is a collaborative industry-academia-research project between Jiangsu Vcare and China Pharmaceutical University. The company holds full rights and intellectual property for the project. Research findings have been successively published in several core domestic and international journals. The project was highlighted by SciBX (published by Nature), which rated Vicagrel as "one of the most commercially promising projects in this field of novel drugs."
Related News
11
2025
/
08
August 8, 2025 – Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced today that it has entered into an exclusive strategic partnership with Huadong Medicine (Hangzhou) Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (000963.SZ, "Huadong Medicine"), for the commercialization rights of Jiangsu Vcare’s innovative product VC005 tablets in mainland China.
View Details
31
2025
/
07
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the completion of full patient enrollment for its Phase II clinical trial of the self-developed, next-generation highly selective JAK1 inhibitor, VC005 topical gel, for the treatment of mild-to-moderate Atopic Dermatitis (AD). This marks a significant milestone in the VC005 gel development program.
View Details
03
2025
/
07
Recently, the NDA for Eratrectinib (VC004) capsules, a next-generation anti-resistance TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has been officially accepted by China's NMPA. Previously granted priority review designation, the drug holds promise as a new treatment option for patients with advanced solid tumors.
View Details
30
2025
/
05
Recently, Eratrectinib (VC004) capsules, a self-developed next-generation anti-resistant TRK inhibitor by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), were included in the priority review list by the NMPA, through public notice. This milestone positions the drug within the first tier of next-generation anti-resistant products targeting the same mechanism in China.
View Details
21
2025
/
05
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the completion of patient enrollment for its self-developed Class 1 innovative antiplatelet drug, Vicagrel Capsules, in a Phase III clinical trial conducted in China. This study evaluates the efficacy and safety of Vicagrel compared to Clopidogrel in patients with acute coronary syndrome (ACS). The milestone marks a critical step toward Vicagrel’s potential market approval.
View Details
09
2025
/
05
On May 8, 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) achieved another major milestone in its self-developed second-generation highly selective JAK1 inhibitor, VC005 tablets. The project, intended for the oral treatment of non-segmental vitiligo received official IND approval from the NMPA (Application No.: CXHL2500200).
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn